These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 22069522)

  • 1. The hepatitis C virus glycan shield and evasion of the humoral immune response.
    Helle F; Duverlie G; Dubuisson J
    Viruses; 2011 Oct; 3(10):1909-32. PubMed ID: 22069522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies.
    Lavie M; Hanoulle X; Dubuisson J
    Front Immunol; 2018; 9():910. PubMed ID: 29755477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
    Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
    Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
    J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural perspectives on HCV humoral immune evasion mechanisms.
    Sevvana M; Keck Z; Foung SK; Kuhn RJ
    Curr Opin Virol; 2021 Aug; 49():92-101. PubMed ID: 34091143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.
    Pantua H; Diao J; Ultsch M; Hazen M; Mathieu M; McCutcheon K; Takeda K; Date S; Cheung TK; Phung Q; Hass P; Arnott D; Hongo JA; Matthews DJ; Brown A; Patel AH; Kelley RF; Eigenbrot C; Kapadia SB
    J Mol Biol; 2013 Jun; 425(11):1899-1914. PubMed ID: 23458406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-neutralizing antibodies to hepatitis C virus.
    Wahid A; Dubuisson J
    J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus evasion mechanisms from neutralizing antibodies.
    Lorenzo CD; Angus AGN; Patel AH
    Viruses; 2011 Nov; 3(11):2280-2300. PubMed ID: 22163345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.
    Helle F; Vieyres G; Elkrief L; Popescu CI; Wychowski C; Descamps V; Castelain S; Roingeard P; Duverlie G; Dubuisson J
    J Virol; 2010 Nov; 84(22):11905-15. PubMed ID: 20844034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
    Fauvelle C; Felmlee DJ; Crouchet E; Lee J; Heydmann L; Lefèvre M; Magri A; Hiet MS; Fofana I; Habersetzer F; Foung SK; Milne R; Patel AH; Vercauteren K; Meuleman P; Zeisel MB; Bartenschlager R; Schuster C; Baumert TF
    Gastroenterology; 2016 Jan; 150(1):206-217.e4. PubMed ID: 26404951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody response to hepatitis C virus.
    Wang Y; Keck ZY; Foung SK
    Viruses; 2011 Nov; 3(11):2127-45. PubMed ID: 22163337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
    Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
    J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies and pathogenesis of hepatitis C virus infection.
    Fafi-Kremer S; Fauvelle C; Felmlee DJ; Zeisel MB; Lepiller Q; Fofana I; Heydmann L; Stoll-Keller F; Baumert TF
    Viruses; 2012 Oct; 4(10):2016-30. PubMed ID: 23202451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.